Table 2.
Characteristics of all the included studies in meta-analysis
| Study | Year | Type of study | Total patients | Population | G-CSF (n) | Control/placebo (n) | Stem cell source | Conditioning | Type of donor | Dose of G-CSF | Route of G-CSF | Day of G-CSF initiation | MNC (×108/kg)/CD34 (×106/kg) (G-CSF arm) | MNC (×108/kg)/CD34 (×106/kg) (control/placebo arm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bishop/Joshi [11,12] | 2000/2003 | RCT | 50 | A | 26 | 24 | PB | MA | MFD | 10 | SC | 0 | MNC (range): 8.09 (2.95-15.77) | MNC (range): 8.05 (5.38-14.94) |
| CD34 (range): 10.36 (4.02-20.32) | CD34 (range): 8.12 (2.2.5-26.17) | |||||||||||||
| Przepiorka [13] | 2001 | RCT | 42 | A | 21 | 21 | PB | MA | Matched donor | 10 | SC | 1 | MNC (range): 5.8 (2.3-19.1) | 8.3 (2.8-23.8) |
| CD34 (range): 4.8 (2.2-20.5) | CD43 (range): 4.3 (1.9-16.2) | |||||||||||||
| Dallorso-A [14] | 2002 | RCT | 53 | P | 23 | 30 | BM | MFD | 10 | IV | 5 | - | - | |
| Dallorso-B [14] | 2002 | RCT | 38 | P | 20 | 18 | BM | MUD | 10 | IV | 5 | - | - | |
| Ernst [15] | 2008 | RCT | 51 | A, P | 25 | 26 | BM | MA | MFD | 5 | IV | 0 | MNC: >2 | MNC: >2 |
| Ben Othma [16] | 2018 | RCT | 145 | A | 69 | 76 | BM | MA | MFD | 5 | IV | 7 | MNC (range): 2.2 (1-3.87) | MNC (range): 1.8 (0.7-4.16) |
| Schriber-A [17] | 1994 | NRS | 44 | A | 17 | 27 | BM | MA | MFD | - | - | - | ||
| Schriber-B [17] | 1994 | NRS | 38 | A | 13 | 25 | BM | MA | MFD | - | - | - | ||
| Berger [18] | 1999 | NRS | 47 | A | 22 | 25 | BM | MA | MUD | 5 | IV | 1 | MNC (range): 2.75 (1.53-7.5) | MNC (range): 2.5 (1.2-4.25) |
| Ozcan [19] | 2001 | NRS | 56 | A, P | 28 | 28 | PB | MA | MFD | IV | 1 | MNC (range): 7.7 (2.71-29.3) | MNC (range): 6.4 (3.1-38.2) | |
| CD34 (range): 6.4 (2.99-30.8) | CD34 (range): 6.5 (2.1-18.9) | |||||||||||||
| Remberger [20] | 2003 | NRS | 155 | A, P | 66 | 89 | BM, PB | MA | MFD | 5 | IV | 10 | MNC (range): 5.1 (0.8-25.6) | MNC (range): 2.4 (0.7-10.7) |
| Ringdén-A [20] | 2004 | NRS | 1789 | A, P | 501 | 1288 | BM | MFD | - | - | 4 (0-14) | MNC (range): 2.92 (0.02-90) | MNC (range): 2.75 (0.15-73) | |
| CD34 (range): 3.52 (1-82.2) | CD34 (range): 3.5 (1.04-82) | |||||||||||||
| Ringdén-B [20] | 2004 | NRS | 434 | A, P | 175 | 259 | PB | MFD | - | - | 7 (0-14) | MNC (range): 8.4 (0.5-42) | MNC (range): 9.55 (0.5-83) | |
| CD34 (range): 5.7 (1.5-83.5) | CD34 (range): 6.1 (1-70) | |||||||||||||
| Khoury-A [21] | 2006 | NRS | 1435 | A, P | 282 | 1153 | BM | MA | MFD | - | - | 5 (0-7) | - | - |
| Khoury-B [21] | 2006 | NRS | 609 | A, P | 216 | 393 | PB | MA | MFD | - | - | 3 (0-7) | - | - |
| Khoury-C [21] | 2006 | NRS | 675 | A, P | 270 | 405 | BM | MA | MUD | - | - | 6 (0-7) | - | - |
| Ringden [3] | 2010 | NRS | 465 | - | 260 | 205 | BM, PB | MA, RIC | MFD, MUD | - | - | - | MNC (range): 3.8 (0.2-59.3) | MNC (range): 3.2 (0.6-63.8) |
| Singh [22] | 2020 | NRS | 162 | A | 65 | 97 | PB | MA, RIC | MFD, MUD | 5 | - | - | CD34 (range): 6.9 (2.1, 22.5) | CD34 (range): 7.1 (2.1, 25.6) |
| George-A [23] | 2020 | NRS | 1487 | A | 313 | 1174 | PB | MA, RIC | MFD | - | -- | - | - | |
| George-B [23] | 2020 | NRS | 2075 | A | 417 | 1658 | PB | MA, RIC | MUD | - | - | - | - |
RCT: Randomised controlled trial, NRS: Non-randomised study; A: Adult; P: Pediatric; PB: Peripheral blood; BM: Bone marrow; MA: Myeloablative; RIC: Reduced intensity conditioning; MFD: Matched family donor; MUD: Matched unrelated donor; SC: Subcutaneous; IV: Intravenous; MNC: Multinucleated cells.